Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor.

Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor.

Item

http://www.wikidata.org/entity/Q33631378

Q33631378

about

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes Peptibodies: A flexible alternative format to antibodies.Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.ADME of biologics-what have we learned from small molecules?Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics.ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools.Application and challenges in using LC-MS assays for absolute quantitative analysis of therapeutic proteins in drug discovery.Assessment of the metabolism of therapeutic proteins and antibodies.The integration of ligand binding and LC-MS-based assays into bioanalytical strategies for protein analysis.Current industrial practices and regulatory requirements to assess analyte and reagent stability using ligand-binding assays.Bioanalytical approaches to assess the proteolytic stability of therapeutic fusion proteins.Generic method approaches for monoclonal antibody therapeutics analysis using both ligand binding and LC-MS/MS techniques.Overview on biotherapeutic proteins: impact on bioanalysis.Development of a sandwich enzyme-linked immunosorbent assay for dTMP-GH fusion protein by rational immunogen selection.Simultaneous analysis of multiple monoclonal antibody biotherapeutics by LC-MS/MS method in rat plasma following cassette-dosing.Bioanalytical method validation: concepts, expectations and challenges in small molecule and macromolecule--a report of PITTCON 2013 symposium Recommendations for validation of LC-MS/MS bioanalytical methods for protein biotherapeutics.Bioanalytical considerations in the comparability assessment of biotherapeutics.Validation of a biotherapeutic immunoaffinity-LC-MS/MS assay in monkey serum: 'plug-and-play' across seven molecules.Serum sample stability in ligand-binding assays: challenges in assessments of long-term, bench-top and multiple freeze-thaw.Peptibodies: An elegant solution for a long-standing problem.The future of immunocapture-capillary electrophoresis-high resolution mass spectrometry.Validation and life-cycle management of a quantitative ligand-binding assay for the measurement of Nulojix(®), a CTLA-4-Fc fusion protein, in renal and liver transplant patients.Orthogonal tools to help determine the required selectivity of ligand-binding assays in drug development.

P2860

Q28066498-CCBEE6FD-7FCD-4E6F-B20B-5771BD97D77C Q28485340-EDFFCE1D-DB9E-4A6C-8324-6D155622DB9A Q33402480-5786D579-56C1-4979-AF78-D4F3C3E50AD0 Q33431320-8560EEA2-B9A1-4660-8BB1-5B73563FBF49 Q35888359-39FCDA25-AAEB-4C2F-BA29-893CAEDD0101 Q36065589-183E754D-AB9D-4A5C-8507-A9DA06B3BE38 Q38060204-782FEDAB-E88B-469D-968B-F1B2AD9A7588 Q38128342-83E87D4D-5275-410C-872B-638474A8B12C Q38202150-28EBBABB-66FF-4044-90E2-D078B256B58E Q38217623-B6D79275-D13A-4810-9834-86D1F2D50FCE Q38243344-BDEFAC07-4534-4BBE-BA30-060868F48EFF Q38537695-77EA5C97-3526-4689-96F1-4BB310030884 Q38652655-DD9BF122-BEE5-4830-94AD-34FAC833DCA0 Q38663039-E19B3656-1736-4485-9BF0-8507C41D0AA9 Q38663214-F7145130-4253-4D8D-8BC4-1D79DB8186F6 Q41038220-F3AD0E88-20BE-4613-94EA-14AE07961220 Q41910990-2F08B9B9-CCFB-4B39-B8E8-612439682DBB Q42557366-69B76B9B-D8BB-43CF-BBFB-B1AA4C1E04B5 Q43096309-1A6F5072-7F28-4FF2-B7CD-7FFE9403D015 Q44701500-F0E46E94-5F6D-44A7-9462-2DC00C4EB7F7 Q45037829-D39A0BB3-7E02-4992-AA3F-39F7FAEBF868 Q46705457-5BFA8E20-AC23-4E20-89DA-1C0AB0F6C5ED Q47229048-5AF6F1B1-5161-44DA-B2D7-AAB725D204B3 Q47450341-BE7B2420-10BC-44C5-A122-C3FF41177995 Q53100427-0A901991-EEAB-4E79-B57B-0F54A0AE564B Q53281208-4C1A4650-E6A6-4729-ABEC-8DD1EA633E96

P2860

Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor.

Item

http://www.wikidata.org/entity/Q33631378

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu